diaDexus, Inc.

343 Oyster Point Boulevard
94080-1913 South San Fancisco

Phone: +1 650 246-6400
Fax: +1 650-246-6499

Company Contacts
Department/ Name Address

International Sales 343 Oyster Point Boulevard, South San Francisco, CA 94080, USA
Company Figures
Number of employees 50-99
Sales volume 1-9 Mio US $
Year of foundation 1997
Area of business Diagnostics

Company Profile

diaDexus – The PLAC Test for Lp-PLA2
diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.

diaDexus’ lead product, the PLAC® Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rapture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events.

The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis. Over 65 articles and abstracts in peer-reviewed articles and abstracts, involving more than 100,000 subjects, highlight Lp-PLA2 as an important risk factor for cardiovascular disease. For more information regarding the PLAC Test, visit www.plactest.com.

Diabetes Management International BV
DIA. PRO Diagnostic Bioprobes S.r.l.
DI.PRO. Medical Devices
DHC Dr. Herterich & Consultants GmbH

DiagCor (Holding) Company Limited
Diaglobal GmbH
Diagnostic Automation / Cortez Diagnostic Inc.